ValuEngine upgraded shares of Proteostasis Therapeutics (NASDAQ:PTI) from a sell rating to a hold rating in a research report sent to investors on Saturday, ValuEngine reports.

Several other analysts have also issued reports on PTI. Cantor Fitzgerald restated a buy rating and issued a $14.00 price objective on shares of Proteostasis Therapeutics in a research note on Monday, March 25th. Piper Jaffray Companies dropped their price objective on Proteostasis Therapeutics to $5.00 and set an overweight rating on the stock in a research note on Thursday, May 9th. Finally, Zacks Investment Research upgraded Proteostasis Therapeutics from a hold rating to a buy rating and set a $4.50 price objective on the stock in a research note on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $8.70.

PTI opened at $1.12 on Friday. Proteostasis Therapeutics has a 52-week low of $0.94 and a 52-week high of $10.38. The stock has a market cap of $50.19 million, a P/E ratio of -0.70 and a beta of -0.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.29 and a current ratio of 11.30.

Proteostasis Therapeutics (NASDAQ:PTI) last released its earnings results on Wednesday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.11. Proteostasis Therapeutics had a negative return on equity of 84.01% and a negative net margin of 1,307.84%. The business had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.80 million. Equities research analysts predict that Proteostasis Therapeutics will post -1.55 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Proteostasis Therapeutics in the fourth quarter valued at approximately $41,000. Great Point Partners LLC bought a new stake in Proteostasis Therapeutics in the fourth quarter valued at approximately $9,867,000. Hikari Power Ltd bought a new stake in Proteostasis Therapeutics in the first quarter valued at approximately $63,000. Bank of Montreal Can grew its position in shares of Proteostasis Therapeutics by 8,649.2% in the fourth quarter. Bank of Montreal Can now owns 15,486 shares of the company’s stock valued at $51,000 after purchasing an additional 15,309 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Proteostasis Therapeutics by 331.6% in the fourth quarter. Bank of New York Mellon Corp now owns 268,990 shares of the company’s stock valued at $871,000 after purchasing an additional 206,672 shares during the last quarter. Hedge funds and other institutional investors own 60.15% of the company’s stock.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Featured Article: Stock Split

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.